5 assets in ATM-Related Cancer Predisposition

Therapeutic assets addressing ATM-Related Cancer Predisposition, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Niraparib ATM-Related Cancer Predisposition	University of California, San Francisco	P2	B (59)
Olaparib ATM-Related Cancer Predisposition	Beth Israel Deaconess Medical Center	P2	CCC (53)
Talazoparib ATM-Related Cancer Predisposition	M.D. Anderson Cancer Center	P2	CCC (53)
Tamoxifen ATM-Related Cancer Predisposition	European Institute of Oncology	P2	CCC (53)
Irinotecan ATM-Related Cancer Predisposition	University of California, San Francisco	P1	CC (43)